(photo: )

DelSiTech & Bayer partner to develop drug delivery tech

Finnish drug delivery technology and drug development company, DelSiTech, and Bayer have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in ophthalmology.







 (photo: )

Shire gains FDA approval for primary immunodeficiency treatment

The US Food and Drug Administration (FDA) has granted approval for Shire’s Cuvitru in adult and paediatric patients two years of age and older.

 (photo: )

FDA issues draft guiances on next-gen sequencing-based tests

In support of the President Barack Obama’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalised, will provide a flexible and streamlined approach to the oversight of tests that detect medically important differences in a person’s genomic makeup.


 (photo: )

Yorkshire pharma firm targets overseas medicine exports

A new medicines and pharmaceuticals wholesaler and distributor has been launched to solve difficulties faced by millions of people in Iraq in obtaining modern medicines to treat many illnesses effectively.

 (photo: )

Yorkshire medical diagnostic company inks global distribution deal

Yorkshire-based medical diagnostic company Abingdon Health as entered into a multi-year, global distribution agreement with electrophoresis specialist Sebia.


 (photo: )

US approval for Janssen’s Crohn’s disease treatment

Janssen Biotech has announced that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults.

 (photo: )

Novartis receives three nods from FDA

The US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes, Novartis has revealed.